Recent advances in the treatment of patients with obesity and chronic kidney disease
AbstractObesity is a chronic disease characterised by excess adiposity, which impairs health. The high prevalence of obesity raises the risk of long-term medical complications including type 2 diabetes and chronic kidney disease. Several studies have focused on patients with obesity, type 2 diabetes...
Main Authors: | Roshaida Abdul Wahab, Ricardo V. Cohen, Carel W. le Roux |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2023-12-01
|
Series: | Annals of Medicine |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/07853890.2023.2203517 |
Similar Items
-
Obesity Treatments to Improve Type 1 Diabetes (OTID): a randomized controlled trial of the combination of glucagon-like peptide 1 analogues and sodium-glucose cotransporter 2 inhibitors—protocol for Obesity Treatments to Improve Type 1 Diabetes (the OTID trial)
by: Ebaa Al-Ozairi, et al.
Published: (2024-02-01) -
Kidney and cardiovascular-protective benefits of combination drug therapies in chronic kidney disease associated with type 2 diabetes
by: Muhammad Shahzeb Khan, et al.
Published: (2024-08-01) -
The Effect of the Sodium—Glucose Cotransporter Inhibitor on Cognition and Metabolic Parameters in a Rat Model of Sporadic Alzheimer’s Disease
by: Jelena Osmanović Barilar, et al.
Published: (2023-03-01) -
Novel Drugs for the Management of Diabetes Kidney Transplant Patients: A Literature Review
by: Nancy Daniela Valencia-Morales, et al.
Published: (2023-05-01) -
Positive effect of vitamin D supplementation on weight loss in obese patients treated with glucagon-like peptide 1 and lifestyle interventions
by: M.B. Gorobeiko, et al.
Published: (2022-09-01)